Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

Nature Reviews Neurology

Volumn 14, Issue 11, 2018, Pages 639-652

  Hampel, Harald ^a,b,c   O’Bryant, Sid E ^d   Molinuevo, José L ^e   Zetterberg, Henrik ^f,g,h,i   Masters, Colin L ^j   Lista, Simone ^a,b,c   Kiddle, Steven J ^k,l   Batrla, Richard ^m   Blennow, Kaj ^f,g  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^e Barcelonaßeta Brain Research Center   (Spain)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^m Roche Diagnostics Ltd   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BLOOD; EARLY DIAGNOSIS; HUMAN; PERSONALIZED MEDICINE; PROCEDURES;

ALZHEIMER DISEASE; BIOMARKERS; EARLY DIAGNOSIS; HUMANS; PRECISION MEDICINE;

EID: 85054570892     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/s41582-018-0079-7     Document Type: Review

References (131)

1. Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 12, 459–509 (2016)
2. Scheltens, P. et al. Alzheimer’s disease. Lancet 388, 505–517 (2016)
3. Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 15, 673–684 (2016)
4. Lista, S. & Hampel, H. Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease. Expert Rev. Neurother 17, 47–57 (2017)
5. Baldacci, F., Lista, S., Cavedo, E., Bonuccelli, U. & Hampel, H. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases. Expert Rev. Proteomics 14, 285–299 (2017)
6. Heneka, M. T. et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14, 388–405 (2015)
7. Iturria-Medina, Y. et al. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat. Commun. 7, 11934 (2016)
8. de la Monte, S. M. & Tong, M. Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem. Pharmacol. 88, 548–559 (2014)
9. James, B. D. et al. TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia. Brain 139, 2983–2993 (2016)
10. Kovacs, G. G. et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 126, 365–384 (2013)
11. Rahimi, J. & Kovacs, G. G. Prevalence of mixed pathologies in the aging brain. Alzheimers Res. Ther. 6, 82 (2014)
12. Attems, J. & Jellinger, K. A. The overlap between vascular disease and Alzheimer’s disease—lessons from pathology. BMC Med. 12, 206 (2014)
13. Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185 (1992)
14. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131–144 (2010). This comprehensive review summarizes the role of both CSF and plasma biomarkers in the diagnosis of AD as well as in drug discovery and clinical trials
15. Hampel, H. & Lista, S. Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. Nat. Rev. Neurol. 8, 598–600 (2012)
16. Kim, D., Kim, Y. S., Shin, D. W., Park, C. S. & Kang, J. H. Harnessing cerebrospinal fluid biomarkers in clinical trials for treating Alzheimer’s and Parkinson’s diseases: potential and challenges. J. Clin. Neurol. 12, 381–392 (2016)
17. Frisoni, G. B. et al. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 16, 661–676 (2017)
18. Patterson, V., Humphreys, J. & Chua, R. Email triage of new neurological outpatient referrals from general practice. J. Neurol. Neurosurg. Psychiatry 75, 617–620 (2004)
19. The Gerontological Society of America. The Gerontological Society of America Workgroup on cognitive impairment detection and earlier diagnosis: report and recommendations. https://changeagents365.org/resources/ways-to-stay-engaged/the-gerontological-society-of-america/Cognitive%20Impairment%20Recommendations%20Report_GSA.pdf (2015)
20. Chen, L. M., Farwell, W. R. & Jha, A. K. Primary care visit duration and quality: does good care take longer? Arch. Intern. Med. 169, 1866–1872 (2009)
21. Cannon, P. & Larner, A. J. Errors in the scoring and reporting of cognitive screening instruments administered in primary care. Neurodegener. Dis. Manag. 6, 271–276 (2016)
22. Wojtowicz, A. & Larner, A. J. General practitioner assessment of cognition: use in primary care prior to memory clinic referral. Neurodegener. Dis. Manag. 5, 505–510 (2015)
23. Garcia-Ptacek, S. et al. Differences in diagnostic process, treatment and social support for Alzheimer’s dementia between primary and specialist care: results from the Swedish dementia registry. Age Ageing 46, 314–319 (2017)
24. Hampel, H. et al. A precision medicine initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric 20, 107–118 (2017). This landmark paper describes the initiation and development of the APMI
25. O’Bryant, S. E. et al. Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 13, 45–58 (2017). This article provides a comprehensive review of the recent literature on blood-based biomarkers in AD and proposes a novel collaborative paradigm for advancing the field from discovery to the clinic
26. Lista, S. et al. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement. 10, 381–392 (2014)
27. Lista, S. et al. Biomarkers in sporadic and familial Alzheimer’s disease. J. Alzheimers Dis. 47, 291–317 (2015)
28. Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 13, 614–629 (2014)
29. McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 263–269 (2011)
30. Inekci, D., Jonesco, D. S., Kennard, S., Karsdal, M. A. & Henriksen, K. The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer’s disease. Front. Neurol. 6, 90 (2015)
31. Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V. & Chetelat, G. Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer’s disease. Neuroimage Clin. 2, 497–511 (2013)
32. Hampel, H. et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer’s disease: a long-range point of view beyond 2020. Biochem. Pharmacol. 88, 426–449 (2014)
33. Hampel, H. et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 9, 560–574 (2010). This article provides an in-depth and critical description of the role of biomarkers for AD from academic, industry and regulatory viewpoints
34. Hampel, H., Lista, S. & Khachaturian, Z. S. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic gordian knot. Alzheimers Dement. 8, 312–336 (2012). This article is a milestone in the discovery, development, validation and qualification processes of biological markers for AD
35. Cavedo, E. et al. The road ahead to cure Alzheimer’s disease: development of biological markers and neuroimaging methods for prevention trials across all stages and target populations. J. Prev. Alzheimers Dis. 1, 181–202 (2014)
36. Hampel, H. & Lista, S. Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J. Nutr. Health Aging 17, 54–63 (2013)
37. Lista, S. et al. Evolving evidence for the value of neuroimaging methods and biological markers in subjects categorized with subjective cognitive decline. J. Alzheimers Dis. 48 (Suppl. 1), S171–S191 (2015)
38. Trojanowski, J. Q. & Hampel, H. Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. Prog. Neurobiol. 95, 491–495 (2011)
39. Hampel, H. et al. Precision medicine — the golden gate for detection, treatment and prevention of Alzheimer’s disease. J. Prev. Alzheimers Dis. 3, 243–259 (2016). This pivotal article introduces the concept of precision medicine in AD
40. Hampel, H. et al. Precision pharmacology for Alzheimer’s disease. Pharmacol. Res. 130, 331–365 (2018). This landmark article focuses on the paradigm of precision pharmacology, an exploratory and integrative strategy to complex diseases — including AD — aimed at identifying aberrant molecular pathways and predicting their temporal impact at the systems level
41. Hampel, H. et al. Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology. J. Alzheimers Dis. 64, S47–S105 (2018). This paper highlights the development of the precision neurology paradigm in AD and the growing importance of the APMI movement
42. Ferretti, M. et al. Sex differences in Alzheimer disease — the gateway to precision neurology. Nat. Rev. Neurol. 14, 457–469 (2018)
43. Lyman, G. H. & Moses, H. L. Biomarker tests for molecularly targeted therapies — the key to unlocking precision medicine. N. Engl. J. Med. 375, 4–6 (2016)
44. Lista, S. et al. Application of systems theory in longitudinal studies on the origin and progression of Alzheimer’s disease. Methods Mol. Biol. 1303, 49–67 (2016)
45. Noorbakhsh, F., Overall, C. M. & Power, C. Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends Neurosci. 32, 88–100 (2009)
46. Deyati, A., Younesi, E., Hofmann-Apitius, M. & Novac, N. Challenges and opportunities for oncology biomarker discovery. Drug Discov. Today 18, 614–624 (2013)
47. Krutovskikh, V. A. & Herceg, Z. Oncogenic microRNAs (oncomiRs) as a new class of cancer biomarkers. Bioessays 32, 894–904 (2010)
48. Schröder, H., Grösche, M., Adler, M., Spengler, M. & Niemeyer, C. M. Immuno-PCR with digital readout. Biochem. Biophys. Res. Commun. 488, 311–315 (2017)
49. Niemeyer, C. M., Adler, M. & Wacker, R. Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol. 23, 208–216 (2005)
50. Castrillo, J. I. & Oliver, S. G. Alzheimer’s as a systems-level disease involving the interplay of multiple cellular networks. Methods Mol. Biol. 1303, 3–48 (2016)
51. Nakamura, A. et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature 554, 249–254 (2018)
52. Ovod, V. et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 13, 841–849 (2017)
53. Janelidze, S. et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci. Rep. 6, 26801 (2016)
54. Weston, P. S. et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology 89, 2167–2175 (2017)
55. Mattsson, N., Andreasson, U., Zetterberg, H. & Blennow, K. Alzheimer’s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557–566 (2017)
56. O’Brien, J. T. & Herholz, K. Amyloid imaging for dementia in clinical practice. BMC Med. 13, 163 (2015)
57. Henriksen, K. et al. The future of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement. 10, 115–131 (2014)
58. de Almeida, S. M. et al. Incidence of post-dural puncture headache in research volunteers. Headache 51, 1503–1510 (2011)
59. Schneider, P., Hampel, H. & Buerger, K. Biological marker candidates of Alzheimer’s disease in blood, plasma, and serum. CNS Neurosci. Ther. 15, 358–374 (2009)
60. Thambisetty, M. & Lovestone, S. Blood-based biomarkers of Alzheimer’s disease: challenging but feasible. Biomark. Med. 4, 65–79 (2010)
61. O’Bryant, S. E. et al. A blood screening test for Alzheimer’s disease. Alzheimers Dement. (Amst.) 3, 83–90 (2016)
62. van Gool, A. J. et al. Bridging the translational innovation gap through good biomarker practice. Nat. Rev. Drug Discov. 16, 587–588 (2017)
63. Lista, S., Faltraco, F., Prvulovic, D. & Hampel, H. Blood and plasma-based proteomic biomarker research in Alzheimer’s disease. Prog. Neurobiol. 101–102, 1–17 (2013)
64. Naj, A. C. & Schellenberg, G. D. Alzheimer’s Disease Genetics Consortium (ADGC). Genomic variants, genes, and pathways of Alzheimer’s disease: an overview. Am. J. Med. Genet. B Neuropsychiatr. Genet. 174, 5–26 (2017)
65. Bertram, L. & Hampel, H. The role of genetics for biomarker development in neurodegeneration. Prog. Neurobiol. 95, 501–504 (2011)
66. Pimenova, A. A., Raj, T. & Goate, A. M. Untangling genetic risk for Alzheimer’s disease. Biol. Psychiatry 83, 300–310 (2018)
67. Genomes Project, C. et al. A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073 (2010)
68. Genomes Project, C. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015)
69. Snyder, H. M. et al. Developing novel blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement. 10, 109–114 (2014)
70. Galasko, D. & Golde, T. E. Biomarkers for Alzheimer’s disease in plasma, serum and blood — conceptual and practical problems. Alzheimers Res. Ther. 5, 10 (2013)
71. Zipser, B. D. et al. Microvascular injury and blood–brain barrier leakage in Alzheimer’s disease. Neurobiol. Aging 28, 977–986 (2007)
72. Montagne, A. et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296–302 (2015)
73. Lewczuk, P. et al. Electrophoretic separation of amyloid β peptides in plasma. Electrophoresis 25, 3336–3343 (2004)
74. Arvanitakis, Z., Lucas, J. A., Younkin, L. H., Younkin, S. G. & Graff-Radford, N. R. Serum creatinine levels correlate with plasma amyloid beta protein. Alzheimer Dis. Assoc. Disord. 16, 187–190 (2002)
75. Fukumoto, H. et al. Age but not diagnosis is the main predictor of plasma amyloid β-protein levels. Arch. Neurol. 60, 958–964 (2003)
76. 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343–349 (2007)
77. Pannee, J. et al. The amyloid-β degradation pattern in plasma — a possible tool for clinical trials in Alzheimer’s disease. Neurosci. Lett. 573, 7–12 (2014)
78. Lewczuk, P. et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: a multicenter study with multiplexing. Exp. Neurol. 223, 366–370 (2010)
79. Roeben, B. et al. Association of plasma Abeta40 peptides, but not Abeta42, with coronary artery disease and diabetes mellitus. J. Alzheimers Dis. 52, 161–169 (2016)
80. Hilal, S. et al. Plasma amyloid-beta levels, cerebral small vessel disease, and cognition: the Rotterdam study. J. Alzheimers Dis. 60, 977–987 (2017)
81. Lopez, O. L. et al. Plasma amyloid levels and the risk of AD in normal subjects in the cardiovascular health study. Neurology 70, 1664–1671 (2008)
82. Lewczuk, P. et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the task force on biological markers in psychiatry of the world federation of societies of biological psychiatry. World J. Biol. Psychiatry 19, 244–328 (2018)
83. Tzen, K. Y. et al. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer’s disease. ACS Chem. Neurosci. 5, 830–836 (2014)
84. Zetterberg, H. et al. Plasma tau levels in Alzheimer’s disease. Alzheimers Res. Ther. 5, 9 (2013)
85. Mattsson, N. et al. Plasma tau in Alzheimer disease. Neurology 87, 1827–1835 (2016)
86. Mielke, M. M. et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the mayo clinic study on aging. JAMA Neurol. 74, 1073–1080 (2017)
87. Gisslén, M. et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3, 135–140 (2016)
88. Kuhle, J. et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab. Med. 54, 1655–1661 (2016)
89. Rojas, J. C. et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann. Clin. Transl Neurol. 3, 216–225 (2016)
90. Rohrer, J. D. et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87, 1329–1336 (2016)
91. Hansson, O. et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88, 930–937 (2017)
92. Vassar, R. et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999)
93. Wu, G. et al. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer’s disease. J. Neurosci. Res. 90, 2247–2258 (2012)
94. Shen, Y. et al. Increased plasma beta-secretase 1 may predict conversion to Alzheimer’s disease dementia in individuals with mild cognitive impairment. Biol. Psychiatry 83, 447–455 (2018)
95. Hye, A. et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement. 10, 799–807.e2 (2014)
96. O’Bryant, S. E. et al. Validation of a serum screen for Alzheimer’s disease across assay platforms, species, and tissues. J. Alzheimers Dis. 42, 1325–1335 (2014)
97. Yu, S. et al. Serum protein-based profiles as novel biomarkers for the diagnosis of Alzheimer’s disease. Mol. Neurobiol. 55, 3999–4008 (2018)
98. Corso, G. et al. Serum amino acid profiles in normal subjects and in patients with or at risk of Alzheimer dementia. Dement Geriatr. Cogn. Dis. Extra 7, 143–159 (2017)
99. Keller, A. et al. Validating Alzheimer’s disease micro RNAs using next-generation sequencing. Alzheimers Dement. 12, 565–576 (2016)
100. Guo, R. et al. A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer’s disease. J. Alzheimers Dis. 60, 1365–1377 (2017)
101. Anand, S. et al. Discovery and confirmation of diagnostic serum lipid biomarkers for Alzheimer’s disease using direct infusion mass spectrometry. J. Alzheimers Dis. 59, 277–290 (2017)
102. Lista, S., Faltraco, F. & Hampel, H. Biological and methodical challenges of blood-based proteomics in the field of neurological research. Prog. Neurobiol. 101–102, 18–34 (2013)
103. Kiddle, S. J., Voyle, N. & Dobson, R. A blood test for Alzheimer’s disease: progress, challenges and recommendations. J. Alzheimers Dis. 64, S289–S297 (2018)
104. Andreasson, U., Blennow, K. & Zetterberg, H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimers Dement. (Amst.) 3, 98–102 (2016)
105. O’Bryant, S. E. et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement. 11, 549–560 (2015). This article provides a summary of selected pre-analytical methodologies used in several international AD cohort studies and presents advanced guidelines and protocols for pre-analytical methods
106. Jack, C. R. Jr et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539–547 (2016)
107. Lista, S., Dubois, B. & Hampel, H. Paths to Alzheimer’s disease prevention: from modifiable risk factors to biomarker enrichment strategies. J. Nutr. Health Aging 19, 154–163 (2015)
108. Gupta, V. B., Sundaram, R. & Martins, R. N. Multiplex biomarkers in blood. Alzheimers Res. Ther. 5, 31 (2013)
109. Lista, S., Zetterberg, H., O’Bryant, S. E., Blennow, K. & Hampel, H. Evolving relevance of neuroproteomics in Alzheimer’s disease. Methods Mol. Biol. 1598, 101–115 (2017)
110. Brinkmalm, A. et al. Explorative and targeted neuroproteomics in Alzheimer’s disease. Biochim. Biophys. Acta 1854, 769–778 (2015)
111. Blennow, K. & Zetterberg, H. Understanding biomarkers of neurodegeneration: ultrasensitive detection techniques pave the way for mechanistic understanding. Nat. Med. 21, 217–219 (2015)
112. Robin, X. et al. Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels into in vitro diagnostics? Expert Rev. Proteomics 6, 675–689 (2009)
113. Hilario, M. & Kalousis, A. Approaches to dimensionality reduction in proteomic biomarker studies. Brief Bioinform. 9, 102–118 (2008)
114. Hampel, H. et al. Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev. Neurother. 15, 83–105 (2015)
115. Broich, K., Weiergräber, M. & Hampel, H. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements. Prog. Neurobiol. 95, 498–500 (2011)
116. Nistico, G., Broich, K. & Hampel, H. Need for new guidelines for Alzheimer’s disease clinical trials. Eur. J. Neurodegener. Dis. 2, 181–186 (2013)
117. Collins, F. S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793–795 (2015)
118. Dubois, B. et al. Cognitive and neuroimaging parameters and brain amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 17, 335–346 (2018). This landmark manuscript focuses on the INSIGHT-preAD cohort
119. Doecke, J. D. et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 69, 1318–1325 (2012)
120. Mapstone, M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 20, 415–418 (2014)
121. Burnham, S. C. et al. A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study. Mol. Psychiatry 19, 519–526 (2014)
122. Kerr, N. L. HARKing: hypothesizing after the results are known. Pers. Soc. Psychol. Rev. 2, 196–217 (1998)
123. Robinson, S. M., Canavan, M. & O’Keeffe, S. T. Preferences of older people for early diagnosis and disclosure of Alzheimer’s disease (AD) before and after considering potential risks and benefits. Arch. Gerontol. Geriatr. 59, 607–612 (2014)
124. Ashton, N. J. et al. Blood protein predictors of brain amyloid for enrichment in clinical trials? Alzheimers Dement. (Amst.) 1, 48–60 (2015)
125. Aisen, P. S., Vellas, B. & Hampel, H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. Nat. Rev. Drug Discov. 12, 324 (2013)
126. Hampel, H. et al. Biomarkers for Alzheimer’s disease therapeutic trials. Prog. Neurobiol. 95, 579–593 (2011)
127. Vellas, B. et al. Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD task force. Alzheimers Dement. 9, 438–444 (2013)
128. Hood, L. & Flores, M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N. Biotechnol. 29, 613–624 (2012)
129. Gligorijević, V., Malod-Dognin, N. & Pržulj, N. Integrative methods for analyzing big data in precision medicine. Proteomics 16, 741–758 (2016)
130. Younesi, E. & Hofmann-Apitius, M. From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA J. 4, 23 (2013)
131. Hampel, H. et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141, 1917–1933 (2018)